绿康生化(002868) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥78,306,085.94, representing a 24.44% increase year-over-year[3] - The net profit attributable to shareholders was -¥12,536,578.53, a decrease of 270.01% compared to the same period last year[3] - The basic earnings per share were -¥0.08, reflecting a decline of 260.00% year-over-year[3] - The total operating revenue for Q3 2021 was ¥252,150,180.35, an increase of 4.87% compared to ¥240,978,663.96 in the same period last year[33] - The net profit for Q3 2021 was a loss of ¥6,130,103.51, compared to a profit of ¥43,258,069.73 in Q3 2020, representing a significant decline[35] - The basic earnings per share for Q3 2021 was -¥0.04, compared to ¥0.30 in Q3 2020, indicating a significant drop[35] Assets and Liabilities - Total assets increased by 23.23% to ¥1,198,395,248.61 compared to the end of the previous year[4] - The company's total assets increased to ¥1,198,395,248.61 in Q3 2021 from ¥972,502,779.28 in the previous year, marking a growth of 23.23%[31] - The total liabilities rose to ¥456,058,223.90 in Q3 2021, compared to ¥202,559,099.70 in the same period last year, indicating a growth of 125.61%[31] - The total equity attributable to shareholders reached ¥765,148,250.51, while total equity including minority interests was ¥769,943,679.58[45] Cash Flow - The cash flow from operating activities showed a net amount of ¥318,591.85, down 99.55% year-to-date[3] - The net cash flow from operating activities for the current period is CNY 318,591.85, a significant decrease from CNY 71,244,791.39 in the previous period[39] - Cash inflow from operating activities totaled CNY 283,909,384.26, down 3.5% from CNY 293,219,513.42 in the previous period[38] - Cash outflow from operating activities increased to CNY 283,590,792.41, compared to CNY 221,974,722.03 in the previous period, reflecting a 27.8% rise[38] - The net cash flow from investing activities is CNY -237,272,237.01, a decline from CNY 82,303,316.61 in the previous period[39] - The net cash flow from financing activities improved to CNY 164,938,738.37, compared to a net outflow of CNY -58,775,055.23 in the previous period[39] Inventory and Investments - The company reported a significant increase in inventory, which rose by 33.76% to ¥71,597,014.95[8] - The long-term equity investments decreased to ¥42,498,542.60 from ¥56,669,473.21, a decline of 25.00%[31] - Research and development expenses for Q3 2021 were ¥19,888,731.45, up 19.00% from ¥16,711,165.89 in the previous year[34] Shareholder Information - The total number of common shareholders at the end of the reporting period is 9,200[13] - Shanghai Kangyi Investment Co., Ltd. holds 30.43% of shares, totaling 47,291,400 shares[13] - The top ten shareholders hold a significant portion of shares, with the largest shareholder holding over 30%[13] Project Developments - The project for producing 1,200 tons of active bacterial peptide premix and 1,200 tons of veterinary raw materials has been delayed and is now expected to be completed by March 31, 2022[16] - The company is investing approximately RMB 201.17 million in a cogeneration project to ensure stable heating quality and reduce energy costs[17] - The main construction of the cogeneration plant has been completed, and it is currently undergoing acceptance testing before grid connection[17] - The company has faced delays in project construction due to the COVID-19 pandemic and rising raw material costs[15] Fundraising Activities - The company plans to issue convertible bonds with a total fundraising amount not exceeding 305 million yuan, with the investment amount adjusted to 430.686 million yuan[18] - The company received acceptance from the China Securities Regulatory Commission (CSRC) for its application to publicly issue convertible bonds on November 16, 2020[19] - The company decided to terminate the public issuance of convertible bonds due to changes in the external market environment and the impact of the overseas pandemic[21] - The company approved a non-public stock issuance plan on January 23, 2021, aiming to raise up to 305 million yuan[22] - The non-public stock issuance will involve issuing no more than 46,624,751 shares, accounting for 30% of the total share capital before the issuance[22] - The CSRC approved the company's non-public stock issuance on June 16, 2021, allowing the issuance of up to 46,624,751 new shares[24] Business Structure Optimization - The company completed the deregistration of its wholly-owned subsidiary, Green康 Hong Kong, to optimize its business structure and reduce management costs[26] Cash and Cash Equivalents - As of September 30, 2021, the company's cash and cash equivalents amounted to approximately 121.97 million yuan, down from 194.26 million yuan at the end of 2020[28] - The total cash and cash equivalents decreased by CNY 72,293,497.73, contrasting with an increase of CNY 93,675,190.19 in the previous period[39]